Cygnal Therapeutics Stock
Cygnal Therapeutics is a biotechnology company
Sign up today and learn more about Cygnal Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Cygnal Therapeutics Stock
Cygnal Therapeutics is developing drugs to manipulate Exoneural Biology for the treatment of cancer, immunological diseases, and regenerative processes. Powered by a comprehensive, cutting-edge neurotechnology platform, They are discovering new dimensions of neural function. Cygnal was founded by Flagship Pioneering in the VentureLabs innovation foundry.
Investors
Flagship Pioneering
Tessera Therapeutics, Indigo, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
Funding History
October 2019 | $65.0M |
---|
Management
Principal / Co-Founder, Flagship Pioneering / Cygnal Therapeutics
Jordi Mata-Fink
Partner / Founding President & CEO, Flagship Pioneering / Cygnal Therapeutics
Avak Kahvejian
Chief Medical Officer
John Wagner
VP Bioinformatics
Hongyue Dai
Founder and CEO / Founding Chairman, Flagship Pioneering / Cygnal Therapeutics
Noubar Afeyan
Chief Business Officer
Elaine Caughey
Press
aacrjournals - Dec, 20 2023
CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism ...bioprocessintl - Dec, 20 2023
BeiGene founder honored at BWB - BioProcesszpr - Nov, 16 2020
http://www.prnewswire.com/news-releases/cygnal-therapeutics-named-to-chemical--engineering-news-10-start-ups-to-watch-list-301172960.htmlfiercebiotech - Sep, 17 2020
Cygnal Therapeutics nabs Merck, Takeda vet Wagner for CMOzpr - May, 29 2020
Cygnal Appoints Elaine Caughey as Chief Business Officer